Triumph Capital Management Raises Position in Eli Lilly and Company (NYSE:LLY)

Triumph Capital Management lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 164.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,240 shares of the company’s stock after buying an additional 1,392 shares during the quarter. Triumph Capital Management’s holdings in Eli Lilly and Company were worth $1,305,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Simon Quick Advisors LLC grew its position in shares of Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after buying an additional 278 shares during the last quarter. Clear Harbor Asset Management LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $363,000. Terril Brothers Inc. boosted its position in shares of Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after purchasing an additional 429 shares during the period. Hartline Investment Corp grew its stake in Eli Lilly and Company by 1.1% during the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock worth $12,786,000 after buying an additional 248 shares during the last quarter. Finally, Meritage Portfolio Management lifted its stake in Eli Lilly and Company by 23.4% in the fourth quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock valued at $3,717,000 after buying an additional 1,208 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday. Morgan Stanley increased their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a research note on Friday, February 16th. DZ Bank downgraded Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a research note on Wednesday, February 21st. The Goldman Sachs Group increased their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Finally, Wells Fargo & Company boosted their price objective on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $742.95.

Eli Lilly and Company Trading Down 0.9 %

Shares of LLY traded down $6.85 during mid-day trading on Wednesday, reaching $774.25. The company had a trading volume of 1,349,685 shares, compared to its average volume of 3,049,779. Eli Lilly and Company has a fifty-two week low of $399.26 and a fifty-two week high of $800.78. The firm has a fifty day simple moving average of $761.41 and a 200-day simple moving average of $669.21. The stock has a market cap of $735.66 billion, a price-to-earnings ratio of 133.47, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter last year, the firm earned $1.62 earnings per share. On average, sell-side analysts anticipate that Eli Lilly and Company will post 12.51 EPS for the current fiscal year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.